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Evaluationof the Role of Shiga and Shiga-like Toxins in Mediating
Direct Damage to Human Vascular EndothelialCells
Vernon L. Tesh, James E. Samuel,* Liyanage P. Perera,
John B. Sharefkin, and Alison D. O'Brien

Departmentsof Microbiologyand Surgery, UniformedServices University
of the Health Sciences, Bethesda, Maryland

InfectionwithShigatoxin- andShiga-liketoxin-producingstrainsof Shigelladysenteriaeand
Escherichiacolif respectively,can progressto the hemolytic-uremic
syndrome.It has been hypothesizedthatcirculatingShigatoxin, Shiga-liketoxins,andendotoxinsmaycontributeto the
diseaseby directlydamagingglomerularendothelialcells. The effectsof thesetoxins on HeLa,
Vero,andhumanvascularendothelialcells (EC)wereexamined.ConfluentECweresensitiveto
Shigatoxinbutwereat least106-foldless sensitiveto the toxinsthanwereVerocells.Shigatoxin
werenot cytotoxicanddid not augwas the predominantcytotoxicfactor.Lipopolysaccharides
mentShigatoxin-mediatedtoxicity.Lowerdosesof Shigatoxincausedcytotoxicitywhencoincubatedwith tumornecrosisfactor.The relativeresistanceof EC to Shigatoxin and Shiga-like
toxins may be due to reducedtoxin binding,as low levels of globotriaosylceramide
(Gb3),the
toxin-specificreceptor,werefoundin EC membranes.

Inflammatorybacterial colitis caused by infection with
Shigella species continues to be a majorcause of morbidity
and mortality in underdeveloped countries, especially
among young children [1]. Of particularinterest is Shigella
dysenteriaetype 1, which is capableof causingepidemicoutbreaksof dysentery.In addition, it has recentlybeen shown
that some strainsof Escherichiacoli, particularlyE. coli serotype 0157:H7, can cause hemorrhagiccolitis [2, 3]. Collectively, these E. coli strains are referredto as enterohemorrhagicE. coli (EHEC). S. dysenteriaetype 1 and EHECshare
the characteristicof producinghigh levels of protein toxins
called Shigatoxin or Shiga-liketoxins (SLTsor Verotoxins),
respectively.EHEC may produce two antigenicallydistinct
toxins, designated SLT-I and SLT-II. SLT-I is essentially
identicalto Shigatoxin, and its cytotoxic activityfor Vero or
HeLa cells can be neutralizedwith anti-Shigaantibodies [4,
5]. SLT-II is 567chomologous to Shiga toxin/SLT-I at the
deduced amino acid level, and its cytotoxicityis not blocked
by anti-Shiga toxin antibodies [5, 6].
Shiga toxin and SLTs are holotoxins that consist of a single 32- to 33-kDa A subunit in associationwith a pentamer
of 7.7-kDa B subunits [7]. The A subunitis a specificN-glycosidase that selectively cleaves a single adenine residue
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from the 28S rRNA component of the 60S eukaryoticribosome complex [8, 9]. The B subunitmediatesbindingof the
holotoxin to specificglycolipid receptorsin mammaliancell
membranes [10-13]. Although the precise role of Shiga
toxin and the SLTsin the pathogenesisof bacillarydysentery
and hemorrhagiccolitis, respectively, is not fully understood, there is now convincing evidence to suggestthat the
toxins are importantvirulencefactorsin the developmentof
bloody, edematous vascularlesions of the colon [14]. The
toxins may also participatein the direct killing of colonic
epithelialcells and may provokefluid secretionand diarrhea
in the host [7].
Perhapsthe most serious sequela of colitis caused by S.
dysenteriaetype 1 or EHEC is the progressionof the disease
to the hemolytic-uremicsyndrome(HUS), which is characterized by acute renal failure,thromboticmicroangiopathy,
and thrombocytopenia[15]. Histopathologicstudies of the
kidneysof HUS patientshave shown profoundalterationsin
the glomeruli.Morespecifically,glomerularendothelialcells
(EC) appearswollen, and thereis abundantfibrindeposition
and inflammatorycell influx in the lumina of the glomeruli
[16]. These observations,as well as the criticalrole of EC in
maintainingnormalblood flow [ 17], have led to the concept
that systemicShigatoxin or SLTs may specificallytargetthe
glomerularEC for damageand therebycontributeto the developmentof HUS. In supportof this hypothesis,Obriget al.
[18] showed that Shiga toxin preparationsare cytotoxic for
human umbilical vein EC (HUVEC) in vitro.
In the experimentsreportedhere, we assessed the cytotoxic potential of crudeShigatoxin, SLT-II,and affinity-purified Shiga toxin for confluent human saphenous vein EC
(HSVEC) and HUVEC monolayers. In addition, we compared Shiga toxin-mediatedEC and Vero cell cytotoxicity
and examined the role of lipopolysaccharides(LPS) and recombinanthumantumornecrosisfactor-ain directEC cyto-
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toxicity. Finally, we analyzed toxin binding to intact EC and
quantitated levels of toxin receptor in EC membranes.

Materials and Methods
Bacterial strains and plasmids. S. dysenteriae type 1 strain
3818T produces high levels of Shiga toxin and was isolated from
a patient with severe dysentery in Central America [19]. E. coli
0157:H7 strain 933 produces both SLT-I and II and was isolated from an outbreak of hemorrhagic colitis in the United
States [2, 5]. Toxins used in this study were derived from E. coli
DH5a (Bethesda Research Laboratories, Gaithersburg, MD)
transformed with recombinant plasmids containing the cloned
toxin genes. E. coli (pLPSH3) harborsthe plasmid pBR328 that
contains the entire Shiga toxin operon on a 5.9-kb Bglll-Sall
insert subcloned from pNAS 10 [4,20]. E. coli (pLP32) harborsa
Bluescribe vector (pBS[?] phagemid kit; Stratagene, La Jolla,
CA) with a 3.0-kb Sphl-Kpnl fragment from pNN76 encoding
SLT-II [21, 22]. Clones producing high levels of toxin were
maintained under BL3 -f-EK1 containment [23].
Toxin preparations. LPS were prepared from S. dysenteriae
3818T and E. coli 933 by the hot aqueous-phenol method of
Westphal and Jann [24]. The pooled aqueous phases were dialyzed against nine changes of double-distilled, deionized HjO,
concentrated 10-fold (Amicon, Danvers, MA), and lyophilized.
LPS preparationscontained ^ Mg/mlprotein (BCA protein assay; Pierce Chemical, Rockford, IL). E. coli Ol 11:B4 LPS was
purchased from Sigma Chemical (St. Louis). Concentrated
crude Shiga toxin and SLT-II were prepared from E. coli
(pLPSH3) and E. coli (pLP32), respectively. The strains were
grown at 370C in 50 ml of Luria broth (LB) containing 250
Mg/ml ampicillin for 24 or 48 h with constant agitation. The
bacteria were pelleted by centrifugation, washed, and resuspended in 5.0 ml of LB. The bacteria were disrupted by sonication and the lysates cleared by centrifugation at 12,000 g for 15
min. Toxins in the clarified lysates were concentrated by precipitation with 60(3dsaturated ammonium sulfate. The precipitates
were resuspended in 5.0 ml of PBS and dialyzed overnight
against PBS. Toxins prepared in this manner reproducibly contained ~ 108-109 CDso/ml when assessed by the Vero cell cytotoxicity assay. Purified Shiga toxin was preparedfrom this crude
starting material as described [22, 25]. Briefly, crude toxin was
passed over a DEAE-Sepharose column equilibrated with 0.05
M TRIS buffer and eluted with a gradient of 0-1.0 M NaCl in
0.05 M TRIS buffer. Fractions cytotoxic for Vero cells were
pooled and passed over a chromatofocusing column. Cytotoxic
fractions were pooled, dialyzed, and passed over an antitoxin
affinity column. Shiga toxin was eluted with 0.05 M glycine,
dialyzed against PBS, and stored at 40C until used. Purified
Shiga toxin preparations contained k0. 1 ng/ml endotoxin as
assessed by limulus amoebocyte lysate gelation (Endotect;
Schwarz/Mann Biotech, Cleveland).
Recombinant human tumor necrosis factor-a (rhTNFa).
rhTNFa (lot NBP-802A; 2.7 X 107 units/mg) was the gift of A.
Creasey (Cetus, Emeryville, CA). Before use in cytotoxicity assays, the lyophilized cytokine was resuspended to 260 pg/ml in
sterile pyrogen-free water (Travenol Laboratories, Deerfield,
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IL). The stock preparationswere then diluted in growth medium
as needed.
Tissue culture. Vero and HeLa cells were maintained in Eagle's MEM (Flow Laboratories, McLean, VA) supplemented
with \07c fetal bovine serum, 10 mM L-glutamine, 50 units/ml
penicillin, and 50 Mg/mlstreptomycin. EC were harvested from
adult human saphenous veins (HSV) obtained during coronary
bypass operations as previously described [26]. Vein segments
(~2.5 cm) were transported to the laboratory in chilled blood
with 100 units/ml preservative-freeheparin (Sigma). The HSV
were cannulated and flushed with cold Ca"^- and Mg^ -free
Dulbecco's PBS (PBS-CMF; GIBCO, Grand Island, NY). HSV
were ligated after filling to slight distension with 0.17c CLS II
collagenase (Worthington Diagnostic Systems, Freehold, NJ)
and 0.5^ bovine serum albumin (BSA) in PBS-CMF and immersed in Hanks' balanced salt solution (GIBCO) for 15 min at
370C. HSV were flushed with 10 ml of cold complete medium
(CM) composed of Medium 199 (GIBCO) with 207cfetal bovine
serum (Hyclone Laboratories, Logan, UT), 100 pg/ml heparin
(Sigma), 100 pg/ml L-glutamine, 50 units/ml penicillin, 50 pg/
ml streptomycin (GIBCO), and 2 pg/ml amphotericin B (Fungizone; GIBCO).
The vein contents were centrifuged (200 g, 1 min, 40C), and
the cell pellet was resuspended in 1.0 ml of CM supplemented
with 20 /d/ml EC-mitogen extract prepared from bovine retina
using a modification of a previously described method [27, 28].
The cells were placed in single wells of 24-well plates (Falcon;
Becton Dickinson Labware,Oxnard, CA) coated with 1 pg/cm2
human fibronectin and incubated at 370C in humidified 57c
C02. The other wells were filled with sterile PBS-CMF to minimize changes in osmolality. Cells were fed every other day with
fresh CM containing 10 pl/ml bovine retinal extract (CM-BRE).
When primary cultures became confluent, HSVEC were detached using 0.05% trypsin-0.02% EDTA, washed in CM with
107cserum, and resuspended in CM-BRE. Subsequent passages
of HSVEC were plated on gelatin-coated 25-cm2 tissue culture
flasks or 96-well microtiter plates. All experiments were done
with HSVEC passaged two to five times in vitro.
HSVEC were characterized by inverted-phase microscopic
observation of cell morphology and immunoenzymatic staining
for factor VHI-related antigen (Endo-RAP I.D.; Endotech, Indianapolis). PrimaryHUVEC were the gift of D. Silverman (Department of Microbiology, University of Maryland School of
Medicine, Baltimore). HUVEC were passaged and maintained
as described above.
Cytotoxicity assays. The cytotoxicity of toxin preparations
for Vero cells was determined as described [29]. Vero cells were
plated at ~ 104 cells/well in 96-well plates and incubated overnight at 370C in 57cCO2. Toxin preparations were serially diluted in complete Eagle's MEM medium, and 100 pi of the
dilutions was transferredto the cells. Incubation was continued
for 48 h. The cells were fixed with formalin and stained with
0.137c crystal violet. Absorbance was measured at 620 nm. A
50%cytotoxic dose (CD5o) represents the reciprocal dilution of
toxin necessary to kill 50^ of the Vero cells in a well. The cytotoxic potency of toxin preparationsis defined as the number of
CD50 per milliliter of toxin preparation. Cytotoxicity of toxin
preparations for EC was assessed by hemocytometer counts or
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by spectrophotometry. EC were plated on the interior 24 wells
of gelatin-coated 96-well plates at ~2 X 104cells per well. Exterior wells were filled with PBS-CMF. When the cells reached
confluence, fresh CM-BRE containing the toxin(s) to be assayed
were added to triplicate wells in a total volume of 200 pi. Incubation was continued at 370C in 57c C02. Cells that subsequently detached from the gelatin substratum failed to exclude
trypan blue, or after extensive washing, did not grow when recultured on gelatin-coated plates.
Viable cells were stained for counting in a hemocytometer by
replacing the growth medium with 60 pi of 0.17ccrystal violet in
0.1 M citric acid (pH 7.26). After the cells were incubated with
the dye at 370C for 20 min, the wells were scraped with sterile
pipette tips, and 15 /d of cell suspension was transferredto the
hemocytometer. Stained nuclei were then counted. Cells were
counted using a microtiter plate readeraccording to the method
of Brasaemle and Attie [30]. Cells were washed with warm PBSCMF, and 100 pi of methanol per well was added for 15 min at
room temperature. The methanol was aspirated from the wells,
the plates were air dried, and 100 pi of 0.17c crystal violet was
added to each well for 5 min. After the dye was removed and the
plates dried, each well was washed with HjO, and the stained
cells were solubilized with 100 pi of 27c(wt/vol) sodium deoxycholate. The plates were heated in a microwave oven (Samsung
MW5510; setting 2) for 1 min, and agitated (mini-orbital
shaker, setting 6; Bellco Glass, Vineland, NJ) for 10 min. Absorbance was read at 570 nm. Cell counts were correlated by linear
regression analysis of hemocytometer cgunts of stained nuclei
against absorbance measurements of triplicate serial twofold dilutions of EC. This assay produced a linear standard curve between 1.5 X 103and 6 X 104cells per well (mean R value, .92).
Data were expressed as percentage of viability, which is defined
as (number of cells H-toxin ? background/number of control
cells ? background) X 100. Background absorbance was derived from staining blank wells. Control cells were incubated
with CM-BRE only.
Neutralizationassay. Dilutions of toxins were made in appropriategrowth media in 96-well plates (100 pl/well), and 100
pi of anti-Shiga toxin monoclonal antibody (MAb 13C4) was
added to each well. The plates were agitated, incubated at 370C
in 57cCO2 for 1 h, and kept overnight at 40C. Toxin-antitoxin
mixtures (100 pi) were then added to Vero cells or EC, and
cytotoxicity was determined as described above. An isotypematched MAb directed against the B subunit of cholera toxin
[31] did not affect cytotoxicity in this assay.
Analysis of toxin binding to wholecells. A modification of an
immunofluorescence protocol using a computer-assisted scanning laser instrument (ACAS 470; Meridian Instruments, Okemos, MI) was devised to compare Shiga toxin binding to EC
versus Vero and HeLa cells [20, 32]. Cells were trypsinized and
adjusted to ~5 X 105 cells/ml in cold diluent buffer (phenol
red-free Earle's balanced salt solution [EBSS;GIBCO] containing 10^. fetal bovine serum and 0.1^ Na^). Concentrated
crude Shiga toxin (50 pi; ~ 109Vero cell CD507ml)was added to
450 pi of cells in Eppendorf tubes and agitated at 40C for 60
min. Unless otherwise noted, all binding and washing steps were
done at 40C. Unbound toxin was removed by three washes with
cold diluent buffer.
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The cells were resuspended in 500 pi of a 1:100 dilution of
primary antibody and agitated for 45 min. Primaryantibodies
used were 4F7, monoclonal IgG 1 directed against the A subunit
of Shiga toxin [33]; 13C4, monoclonal IgG 1 directed against the
B subunit of Shiga toxin [34]; and BC5BB12, monoclonal IgGl
directed against the B subunit of SLT-II [35]. Unbound antibody was removed by three washes with diluent buffer,and secondary antibody (500 pi of a 1:100 dilution of a fluorescein
isothiocyanate-conjugated goat F[ab']2anti-mouse IgG; Cappel
Laboratories, Westchester, PA) was added to the cells. After
unbound secondary antibody was washed out, the cells were
treated with 100 pi of a fluorescent nonspecific membrane
probe, l,r-dioctadecyl-3,3,3' ,3'-tetramethyl indocarbocyanine
perchlorate(5 pg/ml in 17cethanol and serum-freeEBSS;Molecular Probes, Eugene, OR) at 370C for 10 min.
After extensive washing with cold serum-free EBSS, the cells
were transferredto flat-bottomed 96-well plates and centrifuged
for 10 min (200 g) at 40C. The plates were immediately scanned
using the Meridian ACAS 470 equipped with a 5-W argon laser
tuned to 488 nm. Laserpower was adjusted to 200 mW and scan
strength adjusted to 357c. The collimated first-orderbeam was
directed through a standard dichroic filter cube. (See [32] for a
more detailed descriptionof laser parameters.)Qualitativeanalysis of Shiga toxin binding was done by microcomputer conversion of fluorescent emissions into a 15-pseudocolor scan based
on fluorescence intensity.
Thin-layerchromatographyof toxin-bindingglycolipids. Total lipid extracts from HSVEC, HUVEC, Vero, and HeLa cells
were subjected to chromatography on aluminum-backed silica
gel thin-layer chromatography plates (silica gel 60; Merck AG,
Darmstadt, FRG) with CHCl3-CH3OH-0.257o aqueous KC1
(5:4:1) as previously described [22, 36]. Purified glycolipids
served as controls. After chromatography, the chromatography
plates were coated with 0.17c polyisobutylmethacrylate (Polyscience, Warrington, PA), air dried, and sprayed with TBS-BSA
(0.1 M TRIS-HC1[pH 7.4], 0.15 M NaCl, 17cBSA). The plates
were overlaid with ~105 CD507ml Shiga toxin in TBS-BSA.
After incubation at 40C, the plates were extensively washed
with PBS and overlaid with MAb 13C4 diluted in TBS-BSA.
Goat anti-mouse IgG labeled with 125Iwas used as secondary
antibody. The plates were washed, air dried, and specific binding was visualized by autoradiography. Relative amounts of
toxin-binding glycolipids were estimated from peak areasof densitometric scans obtained with a densitometer (CS9000U; Shimadzu, Kyoto, Japan) and compared with serial dilutions of the
control glycolipid globotriaosylceramide (Gb3). Autoradiographsof several exposure times for each thin layer chromatography plate were scanned to ensure the peak areas were within the
linear range of the densitometer.
Statistical analysis. The significance of differences between
means of samples was determined by Student's two-tailed t test.
P < .025 was considered significant.

Results
Role of Shiga toxin, SLT-II, and LPS in direct EC cytotoxicity. To assess the cytotoxic potential of Shiga toxin for
HSVEC, various dilutions of crude Shiga toxin preparations
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time (days)

time (days)
Figure 1. Effectof crudeand purifiedShigatoxin on endothelial
cell viability. Confluent human saphenous vein endothelial cell
(HSVEC) monolayerswere incubated with dilutions of (A) crude
or (B) affinity-purifiedShiga toxin. At the indicated time points,
the numbers of viable, adherent cells were determinedand comparedto HSVECculturedin the absence of toxin. Toxin dilutions
were made on the basis of Vero cell 50^ cytotoxic doses (CD50):
S, 109;A, 107;I, 105;T, 103(all CD5o).Errorbars indicate SD.
were incubated with confluent EC monolayers, and the number of viable cells remaining attached to gelatin-coated wells
was determined by hemocytometer counting or spectrophotometry. The incubation of HSVEC with the highest dilutions of crude Shiga toxin resulted in a dose-dependent kill-
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ing of the cells (figure 1A). Cytotoxicity occurred within the
first 24 h of incubation, and EC viability remained reduced
relative to control cells over 72 h. When HUVEC were used
as target cells, the kinetics and dose response of Shiga toxinmediated toxicity were essentially identical to those of
HSVEC (data not shown). Treatment of both EC types with
crude SLT-II preparations killed the cells in a manner similar
to crude Shiga toxin (data not shown). Finally, treatment of
both EC types with affinity-purified Shiga toxin resulted in
killing that was similar to that observed with crude toxin
preparations (figure 1B). Dilutions of the toxins were made
based on cytotoxicity for Vero cells. From these data, we
estimated that 1 EC CD50 was roughly equivalent to 107
Vero cell CD50, or ~ 1.4 X 10~8M Shiga toxin. These results
suggest, therefore, that while confluent human EC derived
from large veins are sensitive to Shiga toxin, they are at least
106-fold less susceptible than Vero cells.
The observation that purified Shiga toxin killed EC in a
manner similar to crude toxin preparations suggested that
Shiga toxin was the primary mediator of cytotoxicity for EC.
However, the effects of small amounts of endotoxin present
in the toxin preparations could not be discounted, especially
in light of recent evidence that nanogram quantities of endotoxins can have profound effects on EC function [37-39].
To more fully assess the role of Shiga toxin in EC cytotoxicity, we incubated the cells with varying amounts of affinitypurified Shiga toxin in the presence or absence of anti-Shiga
toxin MAb (table 1). Even at the highest toxin concentration
tested, cytotoxicity was completely neutralized by antitoxin
antibody. Antibody alone had no effect on cell viability, and
the addition of an irrelevant, isotype-matched MAb did not
block Shiga toxin cell killing (data not shown). The observation that MAb directed against Shiga toxin neutralizes cytotoxicity provides further evidence in support of the concept
that, in vitro, Shiga toxin is the predominant mediator of
direct EC cytotoxicity.
In light of clinical evidence suggesting that patients with
HUS are frequently endotoxemic [40] as well as histopathoTable 1. Neutralizationof endothelialcell (EC) cytotoxicitywith
anti-Shiga toxin monoclonal antibody (MAb).
Durationof EC exposureto toxin
24 h
Toxin dose
in CD50Zml*
109
107
105

No. MAb
42.2 ?17.3
52.7 ?6.0
91.6 ?4.9

72 h

With MAb

No. MAb

With MAb

104.6 ?3.2
100.4 ?6.5
109.1 ?3.2

20.0 ? 5.0
50.1 ?4.9
100.1 ?8.8

96.7 ? 8.6
110.0 ?2.3
106.6 ?3.0

NOTE. ConfluentECwereincubatedfor24 or 72 h withthe indicateddoses
of Shigatoxin,in thepresenceorabsenceof anti-ShigatoxinMAb.Thenumberof
substratum-adherent
cellswasdeterminedas describedin Materials
andMethods.
Dataarepercentages
of viableEC ? SD.
* Numberof Verocell CD50fm\.

348

Tesh et al.

Figure 2. Effect of Shiga toxin (ShT) versuslipopolysaccharides
(LPS) on endothelial cell (EC) viability that was determinedafter
confluent cells were incubated 48 h with ~ 1 EC 50%cytotoxic
dose (1 EC CD50^ 107Vero cell CD5o)of purifiedShT only; 10
Mg/mlLPSderivedfromEscherichiacoli 0111 :B4,E. coli 0157:H7
strain933, or Shigelladysenteriae3818T; or mixturesof 1 EC CD50
ShT and LPS. Errorbars = SD. Differencesbetween sampleswere
analyzed by Student'stwo-tailed t test; P < .025 was significant.

logic data suggesting that endotoxins may contribute to the
pathologic changes in the kidney characteristic of HUS [41],
we queried whether LPS might play a direct role on in vitro
EC killing. We demonstrated that purified LPS derived from
S. dysenteriae type 1 and EHEC strains were not directly
cytotoxic for confluent human EC monolayers (figure 2) or
Vero cells (data not shown) at doses as high as 10 pgjml.
Furthermore, the coincubation of EC with 10-fold dilutions
of LPS and a constant dose of affinity-purified Shiga toxin
(~1 EC CD50) did not have a statistically significant effect
on EC cytotoxicity in comparison with treatment with Shiga
toxin alone (P ^ .025). Thus, while the presence of endotoxins in vivo may be an important factor in the pathogenesis of
HUS, purified LPS alone does not appear to be a major determinant of direct EC cytotoxicity in vitro.
LPS elicits the synthesis and secretion of TNFa by monocytes and macrophages. TNFa may have pleiotropic effects
in vivo, and this cytokine has emerged as a central mediator
in initiating and regulating the complex cascade of events
that results in a procoagulant and proinflammatory state in
the vasculature [42]. However, the contributory effect, if
any, of TNFa in Shiga toxin-mediated direct EC cytotoxicity is not clear. We therefore coincubated EC with dilutions
of Shiga toxin and rhTNFa and assessed EC cytotoxicity. In
the presence of 10 ng/ml rhTNFa, we detected an ~ 100fold reduction in the Shiga toxin EC CD50 (table 2).
Comparative analysis of Shiga toxin and SLT-II binding to
intact cells. Shiga toxin and SLTs bind to specific glycolipid
receptors in the membranes of Vero or HeLa cells [10-13].
Antibody neutralization, competitive binding, and holotoxin dissolution studies have shown binding to be an essen-
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tial step in target cell intoxication and death [5, 43, 44].
Therefore, reduced binding of Shiga toxin and SLT-II to EC
is one possible mechanism to explain the relative insensitivity of EC to the toxins.
To assess toxin binding to intact EC and to compare binding to control cells, we devised an indirect immunofluorescence assay using a computer-assisted laser scanner that converted fluorescence intensity into a pseudocolor spectrum.
To monitor toxin binding, EC, Vero, and HeLa cells were
treated with equivalent doses of Shiga toxin or SLT-II in
suspension, and toxin binding was detected with antitoxin
antibodies and fluorescein isothiocyanate-conjugated secondary antibody. The cells were then treated with a nonspecific, fluorescent membrane intercalator to outline the cells
and allow comparison of levels of toxin-specific fluorescence
within the same field. As shown in figure 3A, in any given
field, virtually every Vero (left panel) or HeLa cell (right
panel) was intensely stained after treatment with Shiga toxin.
Although every cell showed toxin-specific fluorescence, the
intensity varied between cells (i.e., not every cell appeared to
bind toxin equivalently). The fluorescence intensity and
binding pattern of SLT-II for Vero cells was similar to that
seen with Shiga toxin (data not shown). Since essentially
every cell bound Shiga toxin, the binding pattern produced
by the nonspecific membrane probe was nearly identical to
toxin-specific fluorescence (not shown). In contrast to Vero
or HeLa cells, when EC were treated with an equivalent dose
of Shiga toxin or SLT-II, much lower levels of fluorescence
were detected (figure 3B, C, left panels), indicating reduced
toxin binding in comparison to Vero and HeLa cells. As with
the control cells, however, there appeared to be differences
in the amounts of toxin bound to each individual EC. Some
cells showed very low levels of fluorescence; others showed a
more intense, punctate binding pattern. These data suggest
that if toxin binding and cell killing are directly correlated,
then EC may be heterogeneous in terms of sensitivity to
Shiga toxin. Use of the fluorescent membrane probe (figure
3B, C, right panels) clearly showed the outline of the EC
Table 2. Augmentationof endothelialcell cytotoxicityby recombinant human tumor necrosis factor(TNF).
%viability
Toxin dose
(CDso/ml)*
107
105
103
10'
0

No TNF

TNF

56.7
85.6
97.7
105.0

37.4
60.4
81.4
90.3
92.1

NOTE. Confluentendothelialcellswereincubatedin triplicatefor48 h with
the indicateddosesof Shigatoxinin presenceor absenceof rhTNFa.Thenumber
of substratum-adherent
cellswasdeterminedas describedin MaterialsandMethods. Datarepresentmeanvaluesof threeseparateexperiments.
* Numberof Verocell CDso/ml.
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Figure 3. Comparativeanalysisof Shiga toxin and Shiga-liketoxin type II (SLT-II)binding to intact cells. Equivalentnumbersof Vero
cells, HeLa cells, and endothelialcells (EC) were treatedwith 109Vero cell 50%cytotoxic doses of crude toxin preparationsat 40C in the
secondaryantibody.The
presenceof NaN3. Bound toxins weredetectedwith anti-toxinmonoclonal antibodiesand fluorescein-conjugated
cells were outlined by simultaneousstainingwith a nonspecificfluorescentmembraneprobe.Fluorescencewas measuredusinga Meridian
ACAS 470 laserscannerin which fluorescenceintensitywas convertedto the 15 color scale at right.Moving up the scale, colors represent
increasingfluorescenceintensity.A, Vero and HeLa cells (left and rightpanels, respectively)treatedwith Shigatoxin. B, EC treatedwith
Shigatoxin (left) and membraneprobe(right).C, EC treatedwith SLT-II(left) and membraneprobe(right).D, EC treatedwithEscherichia
coli DH5a concentratedsonicatedlysate, (left) and membraneprobe (right).
present in the fields. As a control, concentrated sonicated
lysates were prepared from E. coli DH5a in a manner analogous to that used to concentrate Shiga toxin (see Materials
and Methods). The control lysates showed no binding to EC
(figure 3D, left). In addition, the deletion of primary or secondary antibody from the assay showed that nonspecific
background fluorescence was very low in this procedure
(data not shown). Therefore, the fluorescence detectable in
Shiga toxin-treated cells is specifically due to toxin binding.
These data suggest that one reason EC are less sensitive than
Vero or HeLa cells to the cytotoxic effect of Shiga toxin may
be low levels of toxin binding to the cells.
Comparative quantitative analysis of toxin-specific glycolipid receptors in EC. Toxin-binding glycolipids present in
Vero and HeLa cells and EC were detected by the direct
binding of saturating amounts of Shiga toxin to thin-layer
chromatograms of serial dilutions of membrane total glycolipid extracts (figure 4, lanes 6-15). Glycolipid standards
were used to compare the glycolipids present in each cell line
(figure 4, lanes 1-5, 16). In contrast to Vero and HeLa cells,
the amount of toxin-binding glycolipids detected in EC
membrane extracts prepared from equivalent cell wet
weights was greatly reduced. Bound toxin was detected with
Shiga toxin-specific MAb and 125I-labeledgoat anti-mouse
IgG antibody. Since the amount of toxin-specific glycolipids
present in membrane extracts was previously shown to correlate directly with the amount of bound toxin [45], we quanti-

tated the relative amounts of toxin-binding glycolipids by
direct densitometric scanning of the autoradiographs. HUVEC and HSVEC contained 0.06 and 0.03 nM Gb3/mg of
cells, respectively. In contrast, Vero and HeLa cells contained 80 and 25 nM Gb3/mg of cells, respectively. Thus, the
diminished toxin-binding glycolipid content of EC compared with Vero and HeLa cells directly correlated with reduced Shiga toxin sensitivity and toxin binding.

Discussion
The experimentsreportedhere were designedto examine
the role of crude or purifiedShiga toxin, SLT-II,LPS, and
recombinantcytokines in killing confluent human vascular
endothelial cells and to compare the EC cytotoxicity with
that of other cell lines. The incubationof EC with purified
Shigatoxin resultedin a reductionin the numbersof viable
cells remainingattached to gelatin-coateddishes, and this
activitywas neutralizedby anti-Shigatoxin MAb, suggesting
that Shigatoxin was the primarymediatorof cytotoxicityin
vitro. These resultssupportand extend the findingsof Obrig
et al. [18], who demonstratedthat rabbit polyclonal antiShiga toxin antibodies,as well as heat denaturation,totally
neutralizethe EC cytotoxic potentialof Shigatoxin preparations. These investigatorsalso showed, however,that Shiga
toxin, to a dose of 10-7 M, had a delayed (>48 h) cytotoxic

effecton confluentHUVEC [18]. In contrastto theirstudies,
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we detected a more rapid loss of EC viability, occurring
within the first 24 h of incubation with toxin. These differences in kinetics may be due to differences in the metabolic
activity of the EC used in the cytotoxicity assays. Obrig et al.
[18] cultured different concentrations of HUVEC at 370C
for 12-24 h, and these cells were termed confluent or nonconfluent. We seeded EC, monitored growth using an inverted-phase microscope, and allowed the cells to replicate
to a confluent state over 3-5 days. Since Shiga toxin acts by
inhibiting protein synthesis, differences in target cell metabolic activity may have drastic effects on Shiga toxin sensitivity.
The amount of toxin added to EC was based on the cytotoxicity of the toxin preparations for Vero cells, a cell line
that has been used to characterize toxin activity and toxin-receptor interaction [7]. While EC are susceptible to Shiga
toxin, they are at least 106-fold less sensitive than Vero cells.
On the basis of the cytotoxic potential of Shiga toxin for Vero
cells (1 CD50 - 1 pg of toxin), we estimate that 1 EC CD50 is
- 1.4 X 10-8 M or ~ 10 gg of toxin. As previously reported
for other cytotoxicity assays using Shiga toxin and SLTs [46,
47], we noted a shallow dose response curve, that is, incubation of EC with concentrations of Shiga toxin that differ 100fold produced only slight changes in percentages of viability
(compare 109vs. 10' CD50, figure 1). In addition, we isolated
viable EC, even when the cells were incubated with - 10 EC
CD50 of Shiga toxin. Although previous studies have clearly
demonstrated differential cytotoxicity between confluent
and nonconfluent HUVEC [18], our data suggest that even
within a population of confluent EC, there may be heterogeneity in terms of susceptibility to Shiga toxin.

ORIGIN

Figure 4. Quantitationof toxinspecific glycolipid receptor in human saphenous vein endothelial
cells (HSVEC), human umbilical
vein endothelial cells (HUVEC),
Vero cells, and HeLa cells. Shiga
toxin was bound to glycolipidsseparated by thin-layerchromatography, detected with anti-Shiga
toxin monoclonal antibody and
'25I-labeledgoat anti-mouse IgG
antibody,and visualizedby autoradiography.By lane: 1-5, 100, 50,
10, 5, and 1 ng globotriaosylceramide (Gb3), respectively;6, 7, glycolipids from I and 3 mg of Vero
cells, respectively;8, 9, glycolipids
from 1 and 3 mg of HeLa cells, respectively; 10-12, glycolipidsfrom
1, 3, and 10 mg of HSVEC,respectively; 13-15, glycolipids from 1,
3, and 10 mg of HUVEC, respectively; 16, 1 gg eachof standardglycolipids lactosylceramide(CDH),
Gb3, and globotetraosylceramide
(Gb4). All cell masses are expressedaccordingto wet weight.

Several lines of evidence suggest that endotoxins may contribute to the development of HUS. Bertani et al. [41] demonstrated that when rabbits were infused with E. coli
0111:B4 LPS, marked damage to glomerular EC became
apparent within 5 min. Changes in EC morphology preceded
polymorphonuclear cell infiltration and fibrin deposition.
These changes were consistent with those seen in the kidneys
of HUS patients [16]. Barrett et al. [48] showed that a single
sublethal dose of endotoxin given to rabbits 3 days after the
initiation of continuous SLT-II infusion enhances the lethal
effect of the toxin. In the in vitro cytotoxicity assays reported
here, however, purified LPS derived from S. dysenteriae type
1 or EHEC strains was not directly cytotoxic for EC at doses
as high as 10 Ag/ml. This finding is in accordance with earlier
studies showing that HUVEC are refractory to both LPS-mediated direct cytotoxicity and changes in EC function at
doses as high as 100 ,g/ml [49, 50]. In addition, we have
shown that the addition of anti-Shiga toxin MAb to crude
toxin preparations neutralizes cytotoxicity, and the coincubation of EC with LPS and purified Shiga toxin neither enhanced nor inhibited EC cytotoxicity. However, the correlation of our in vitro cytotoxicity data with animal models of
HUS should be made with caution. The capacity of endotoxins to mediate alterations in cellular functions, particularly
through the elicitation of endogenous cytokines, is now well
documented [42, 51]. Thus, the contributory effect of endotoxins in HUS may be mediated through changes in EC or
inflammatory cell functions that have yet to be fully elucidated.
Our data suggest that in the presence of the cytokine
TNFa, the Shiga toxin EC CD50 may be reduced from
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~ lO"8M to as low as ~ lO"10M (table 2). Although free
Shiga toxin or SLTs in human sera have not been quantitated, it is not unreasonableto speculatethat this lower dose
of toxin may be in the physiologicallyrelevantrange[52]. In
addition, Shiga toxin may exacerbateany cytotoxic effects
mediated directly by cytokines. rhTNFa at 20 ng/ml or recombinant human interleukin-10at 100 pg/ml have been
demonstratednot to be directlycytotoxic for HUVEC [53].
However, in the presence of the protein synthesis inhibitor
cycloheximide or the RNA synthesis inhibitoractinomycin
D, HUVEC have been shown to be sensitized to the cytotoxic effectsof these cytokines [53]. Therefore,by inhibiting
de novo protein synthesis, Shiga toxin and SLTs may act to
block the protective mechanism(s) necessary to overcome
cytokine-mediateddirect cytotoxicity.
We used an indirect immunofluorescenceassay to monitor the binding of Shiga toxin to EC. Toxin-specificbinding
to EC was reducedrelativeto Vero and HeLa cells. We also
noted cell-to-cell variationsin toxin binding when Vero or
HeLa cells or EC were treatedwith equivalentdoses of Shiga
toxin. Again,this suggeststhatthe cells mayconsistof heterogeneous populations in terms of the capacity to bind Shiga
toxin. Toxin bindingstudiesusing Shigatoxin-sensitive and
resistantHeLa cell lines have shown that 10-folddifferences
in toxin binding sites can produce 109-fold variabilityin
toxin sensitivity [46, 47]. Thus, the minute differencesin
fluorescencewe observed among cells in the toxin binding
experiments may represent profound differences in Shiga
toxin sensitivity. To more directly compare differencesin
toxin binding, we examined the glycolipid components of
the cell membranes.Both EC types contained ~ 1000-fold
less Gb3 than did Vero cells. Thus, the relativeinsensitivity
of human EC derivedfromlargeveins may be directlycorrelated with reduced numbersof toxin-specificmembranereceptors,and our data supportearlierstudiesshowinga correlation of Shigatoxin sensitivitywith membraneGb3content
[45, 47, 54].
Ourdatademonstratingthe relativeinsensitivityof human
vascularEC to Shiga toxin and the paucity of toxin-specific
membranereceptorssuggest that the use of these cells may
not representthe most appropriatein vitro model of HUS.
Histopathologicstudieshave shown, however,thatglomerular EC damage is a hallmarkof HUS [16, 41]. Boyd and
Lingwood[45] showed that Gb3 is the predominantneutral
glycolipid in human renal tissue; their values were ~2- to
30-fold greaterthan the amount of Gb3 we detected in EC.
Although the amount of glycolipid in a complex tissue sample may not accuratelyreflectthe relativeamount in a particular cell type, the data suggest that EC derived from large
veins may differin theirtoxin-receptorcontent fromglomerular endothelial cells. Finally, it is importantto note that
human vascularEC and glomerularEC are functionallyand
morphologicallydistinct cells. Glomerular EC are highly
fenestratedand coated with a sialoglycoprotein-richanionic
glycocalix [55]. The structuraland functional differencesin
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EC may include differentialresponsesto Shigatoxin or LPS.
There is one reportthat endotoxins are directlycytotoxic for
human glomerularendothelialcells [56]. Furtherstudies on
the effect of Shiga toxin and endotoxin on human glomerularcells are clearlywarrantedand arecurrentlyin progressin
our laboratory.
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